DJIA 18,080.14 21.45 0.12%
NASDAQ 5,092.09 36.02 0.71%
S&P 500 2,117.69 4.76 0.23%
market minute promo

Merck & Co., Inc. (NYSE: MRK)

57.60 0.09 (0.16%)

REAL-TIME: Last trade at

company name or ticker

Recent Quotes

MRK $57.60 0.16%
Company Photos
(Click to zoom)
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $57.85
Previous Close $57.51
Daily Range $57.51 - $58.19
52-Week Range $52.49 - $63.62
Market Cap $163.5B
P/E Ratio 14.13
Dividend (Yield) $1.80 (3.1%)
Ex-Dividend Date
Dividend Pay Date
Volume 7,866,296
Average Daily Volume 11,755,025
Current FY EPS $3.39




Drug Makers

Merck & Co., Inc. (MRK) Description

A global research-driven pharmaceutical company that discovers, develops, manufactures and markets a range of innovative products to improve human and animal health. Website:

News & Commentary Rss Feed

Are Biosimilars the Next Big Thing in Biotech?

Biosimilars could soon become a major force in biotech as multiple top-selling biologics lose patent protection. So are biosimilars the next big thing in biotech, or are they overhyped?

Merck Reports Encouraging Data on HCV Combo Candidate - Analyst Blog

AbbVie's HCV Cocktail Treatment Under FDA Priority Review - Analyst Blog

Seeking Alpha's Biotech Weekly: Gilead Isn't Perfect, Biogen-Bass, Spring Fever, And More

Today's Top Performers In Drugs

Illumina's Earnings Set Positive Tone for Biotech

What's behind Illumina's remarkable earnings beat, and what could it mean for biotech stocks?

Morgan Stanley Alert: Gilead Investors Don't Have The Whole Story

Analyst: Biogen Will Miss On Tecfidera Sales; No Threat To Gilead's Harvoni

IHE, MRK, BMY, LLY: Large Inflows Detected at ETF

Is Immuno-Oncology the Best Area of Biotech to Invest in Right Now?

Immuno-oncology has become a major focus among big pharma companies these days. Should investors jump on this trend?

See More MRK News...

MRK's Top Competitors

MRK $57.60 (0.16%)
Current stock: MRK
JNJ $101.08 (0.62%)
Current stock: JNJ
NVS $104.28 (-1.16%)
Current stock: NVS
RHHBY $36.24 (-0.83%)
Current stock: RHHBY